KAWAI N, Ikematsu H, Iwaki N, Kawashima T, et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect. 2007 Jun 29
OBJECTIVE: To compare the persistence, susceptibility and resistance of influenza A and influenza B viruses in oseltamivir therapy in outpatients of various ages. METHODS: Virus isolation was done before and 4-6 days after the initiation of oseltamivir therapy for 148 patients with influenza A/H3N2 and for 66 with influenza B in the 2003-2004 and 2004-2005 influenza seasons. Neuraminidase inhibition assay and neuraminidase or hemagglutinin sequence analysis were done using influenza viruses isolated from these patients. RESULTS: The virus isolation rate after oseltamivir therapy was significantly higher for influenza B (33.3%) than for influenza A/H3N2 (12.8%, p<0.001). The mean IC(50) values before and after oseltamivir therapy were significantly higher in patients with influenza B (10.82 and 11.32nM, respectively) than in patients with influenza A/H3N2 (0.94 and 0.81nM, respectively, both p<0.001). No significant differences in IC(50) among each age group, or no significant increase in IC(50) from before to after oseltamivir therapy was observed. Neuraminidase or hemagglutinin sequence analysis revealed no known genotype with resistance to oseltamivir. CONCLUSION: Virus persistence after oseltamivir therapy was longer and IC(50) values were higher in influenza B than influenza A.
See Also:
Latest articles in those days:
- Highly pathogenic avian influenza as a systemic risk - implications for control and preparedness 17 hours ago
- Multiple introductions and spread of novel reassortant highly pathogenic avian influenza A (H5N1) clade 2.3.4.4b viruses via wild birds, South Korea, 2024-2025 17 hours ago
- [preprint]The mammalian-adaptive PB2-E627K substitution preserves viral fitness of clade 2.3.4.4b H5N1 HPAIV in birds 1 days ago
- Mallard super-shedders of avian influenza exhibit distinct cloacal microbial abundance profiles 1 days ago
- A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge 1 days ago
[Go Top] [Close Window]


